Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) was upgraded by equities research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Thursday.

ARWR has been the subject of a number of other research reports. Piper Jaffray Companies reiterated a “hold” rating and set a $2.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Friday, July 28th. Jefferies Group LLC restated a “hold” rating and issued a $2.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Friday, August 4th. One research analyst has rated the stock with a sell rating and five have issued a hold rating to the company. The company has a consensus rating of “Hold” and an average price target of $1.80.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) opened at 2.58 on Thursday. The company’s market capitalization is $192.91 million. Arrowhead Pharmaceuticals has a 52 week low of $1.20 and a 52 week high of $8.09. The company has a 50 day moving average price of $1.82 and a 200-day moving average price of $1.79.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.06. The business had revenue of $9.34 million during the quarter, compared to the consensus estimate of $5.29 million. Arrowhead Pharmaceuticals had a negative return on equity of 46.73% and a negative net margin of 201.84%. On average, equities analysts anticipate that Arrowhead Pharmaceuticals will post ($0.42) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Rating Upgraded by ValuEngine” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/08/26/arrowhead-pharmaceuticals-inc-arwr-stock-rating-upgraded-by-valuengine.html.

Several institutional investors have recently made changes to their positions in the company. UBS Asset Management Americas Inc. increased its position in Arrowhead Pharmaceuticals by 414.7% in the first quarter. UBS Asset Management Americas Inc. now owns 66,400 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 53,500 shares during the last quarter. Virtu KCG Holdings LLC increased its position in Arrowhead Pharmaceuticals by 115.6% in the second quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 53,215 shares during the last quarter. Teachers Advisors LLC increased its position in Arrowhead Pharmaceuticals by 18.0% in the fourth quarter. Teachers Advisors LLC now owns 112,642 shares of the biotechnology company’s stock valued at $175,000 after buying an additional 17,201 shares during the last quarter. SG Americas Securities LLC increased its position in Arrowhead Pharmaceuticals by 287.9% in the first quarter. SG Americas Securities LLC now owns 100,747 shares of the biotechnology company’s stock valued at $186,000 after buying an additional 74,776 shares during the last quarter. Finally, Wells Fargo & Company MN increased its position in Arrowhead Pharmaceuticals by 144.8% in the first quarter. Wells Fargo & Company MN now owns 150,346 shares of the biotechnology company’s stock valued at $278,000 after buying an additional 88,933 shares during the last quarter. Hedge funds and other institutional investors own 29.89% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Stock Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.